ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PFSA / financials
VJET (30) NXGL (28) IVF (35) BJDX (38) ⌘ Pro Terminal β†’

Profusa Inc. (PFSA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.65 -7.01% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.64

Profusa Inc. (PFSA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $394.3K
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PFSA Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PFSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Profusa Inc. (NASDAQ: PFSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.65 (-7.01% 1D, market cap $394.3K). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PFSA ranks #617 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PFSA compare to VJET and NXGL in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), PFSA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, VJET (Flyte Aviation Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M) and NXGL (NexGel Inc) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M). Among the 5-stock peer group, PFSA leads on earnings multiple (N/A) while PFSA leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PFSA?
β–Ό

Per PFSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001859807), Profusa Inc. generated $77.6M in revenue (+77476.8% YoY), -$35.8M in net income, and -$16.3M in free cash flow against $3.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.64 (-1.45%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (7)Whales (3)SEC (10)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
$1811 Bull$1 Base$0 Bear
πŸ“¬ FREE PFSA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PFSA)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY PFSA SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 1/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 35.2 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$1.28-31.3% Next Q
Q2 (-2Q)
40
Grade D$0.88-11.4% Next Q
Q3 (-1Q)
38
Grade E$0.78-16.7% Next Q
Current
35
Grade D-$0.65-8.5% Hist 90D Ξ±
Trajectory: D (43) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PFSA Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PFSA currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.89) and Max Pain ($0.68) forces dealer call-delta covering toward $1,811.25.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PFSAβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPFSA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How PFSA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$77.6MGross Profit $40.3M (52%)Cost of Sales $37.2MOp Profit $0 (0%)OpEx (R&D/SG&A) $40.3MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $4.2M
FY24
Rev $100.0K
FY25
Rev $77.6M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$77.6M52%-35.7%-$35.8M-$16.3M-45%
FY 2024$100.0K52%-80%-$9.2M-$2.1M-45%
FY 2023$4.2M52%-35.7%$1.2M-$2.1M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PFSA)

  • βœ“Walkthrough of PFSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PFSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -98.75%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-04O $0.70H $0.70L $0.65C $0.65VOL 191.6K
SUP: $0.23SMA50: $1.89SMA200: $87.32
$1,687.7$1,230.5$773.2$316.0$-141.25SUP $0.23$0.652026-05-052026-06-182026-08-052026-09-182026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PFSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PFSA Butterfly Map β†’ + Track PFSA β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +77476.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PFSA today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PFSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PFSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PFSA)

Health Care Rank #617 of 1015 βš”οΈ VJET vs PFSA Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PFSA vs. VJET, NXGL, IVF, BJDX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Profusa Inc. (PFSA) ranks #617 by composite RQD confidence (35/100, grade D-) and #1015 by equity capitalization ($394.3K). Within this direct 5-issuer industry benchmark cohort, PFSA leads on earnings valuation at N/A trailing P/E, while PFSA leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. BJDX currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with PFSA at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PFSA ACTIVE
Profusa Inc.
D- 35/100 β€” β€” -35.0% -7.01% $394.3K Benchmark Subject
VJET
Flyte Aviation Inc.
E 30/100 β€” 92.3% -35.0% +0.17% $1.2M /vjet-vs-pfsa β†’
NXGL
NexGel Inc
E 28/100 β€” 39.5% -35.0% +7.98% $1.8M /nxgl-vs-pfsa β†’
IVF
INVO Fertility Inc.
D- 35/100 β€” 96.0% -35.0% -4.19% $2.1M /ivf-vs-pfsa β†’
BJDX
Bluejay Diagnostics Inc.
D- 38/100 β€” β€” -35.0% -4.74% $2.4M /bjdx-vs-pfsa β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001859807 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Profusa Inc. (PFSA) reported GAAP revenue of $77.6M (+77476.8% vs. FY2024 revenue of $100.0K , and +1736.4% cumulative change since FY2023) , GAAP net income of -$35.8M, operating cash flow of -$16.2M, and free cash flow of -$16.3M (-686.8% YoY). On the balance sheet, PFSA closed FY2025 with $3.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $77.6M -$35.8M -$16.2M -$16.3M $3.8M β€”
FY2024 (FY) 2024-12-31 $100.0K -$9.2M -$2.1M -$2.1M $3.1M β€”
FY2023 (FY) 2023-12-31 $4.2M $1.2M -$2.1M -$2.1M β€” β€”

3. PFSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PFSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Profusa Inc. (NASDAQ: PFSA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $0.65 (-7.01% 1D, market cap $394.3K). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, PFSA ranks #617 in composite RQD confidence.

How does PFSA compare to VJET and NXGL in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PFSA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, VJET (Flyte Aviation Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $1.2M) and NXGL (NexGel Inc) posts a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.8M). Among the 5-stock peer group, PFSA leads on earnings multiple (N/A) while PFSA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PFSA?

Per PFSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001859807), Profusa Inc. generated $77.6M in revenue (+77476.8% YoY), -$35.8M in net income, and -$16.3M in free cash flow against $3.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PFSA trading relative to its 50-day, 200-day, and 52-week technical levels?

PFSA last traded at $0.65 (-7.01% on volume of 191,602 shares), positioning the stock -65.61% below its 50-day simple moving average ($1.89) and -99.26% below its 200-day simple moving average ($87.32). Across its 52-week range of $0.65 to $1,725.00, PFSA sits at the 0.0% percentile with a 14-day RSI of 35.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.73).

Direct Sub-Reports: PFSA RQD Cockpit PFSA 12M Forecast PFSA Earnings & Move PFSA Dividends & DRIP PFSA Insiders & 13F PFSA Whale Options PFSA Profit Sankey PFSA News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

PFSA β€” Profusa Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Profusa Inc. (PFSA) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.65 (-7.01% 1D, market capitalization $394.3K).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Profusa Inc. Is a NASDAQ-listed issuer in the Health Care sector and the Medical/Dental Instruments industry, with a market capitalization of $0.0B. Gross, operating, and net margins are each reported as 0%. Revenue for FY 2025 is reported as β€” and for FY 2024 as $0.1M, section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Profusa Inc. (PFSA) reported $77.6M in annual revenue (up from $100.0K in FY2024, +77476.8% YoY) and -$35.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($4.2M revenue, $1.2M net income) through FY2025, PFSA scaled operating cash flow to -$16.2M and free cash flow to -$16.3M, backed by $3.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.65 – $1,725.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies are mapped, and no proprietary signals are recorded. A prospective investor should monitor whether future filings identify dependencies on suppliers or customers, as the current data does not provide them.

  • Key Question #1: Can PFSA sustain or expand its β€” operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $77.6M and free cash flow of -$16.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PFSA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PFSA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Profusa Inc. (PFSA) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PFSA Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PFSA Bull vs. Bear Conversation Board β€” What's Your Call at $0.65?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PFSA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PFSA:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER β€’ Growth & Tech Investor πŸ‚ BULLISH 🎯 Target: $0.80 (+14.3%)
πŸ“Œ Pinned Debate

The RQD rating's whale 13F flow pillar scores 15 out of 20, indicating institutional accumulation and options positioning that partiall

The RQD rating's whale 13F flow pillar scores 15 out of 20, indicating institutional accumulation and options positioning that partially offsets weak fundamentals.. When you look under the hood at PFSA, Fundamental Cash Engine is 7/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $1965.00. My 12M target is $0.80.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” PFSA's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.59 (-15.7%)
Spot @ $0.70

Operating losses widened to -$27.7M in FY 2025 against $1.8M of reported cash, with ROIC at -35% and FCF yield at 0%.

Fading this rally in PFSA at $0.70. Operating losses widened to -$27.7M in FY 2025 against $1.8M of reported cash, with ROIC at -35% and FCF yield at 0%.. With a beta of 1.0 and the stock sitting at $0.70 (52-wk range $0.69–$1965.00), the easy multiple expansion is already priced in.

LIVE TAPE